ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee

O. Michielin, A. van Akkooi, P. Lorigan, P. A. Ascierto, R. Dummer, C. Robert, A. Arance, C. U. Blank, V. Chiarion Sileni, M. Donia, M. B. Faries, C. Gaudy-Marqueste, H. Gogas, J. J. Grob, M. Guckenberger, J. Haanen, A. J. Hayes, C. Hoeller, C. Lebbé, I. Lugowska, M. Mandalà, I. Márquez-Rodas, P. Nathan, B. Neyns, R. Olofsson Bagge, S. Puig, P. Rutkowski, B. Schilling, V. K. Sondak, H. Tawbi, A. Testori & U. Keilholz Department of Oncology, University Hospital Lausanne, Lausanne, Switzerland; Department of Surgical Oncology, The Netherlands Cancer Institute e Antoni van Leeuwenhoek, Amsterdam, The Netherlands; Division of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy; Department of Dermatology, University Hospital Zürich, Zürich, Switzerland; Department of Medicine, Gustave Roussy, Villejuif; Paris-Saclay University, Le Kremlin-Bicêtre, Paris, France; Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Experimental and Clinical Oncology, Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy; National Center for Cancer Immune Therapy, Department of Oncology, Herlev and Gentofte Hospital, Herlev; University of Copenhagen, Copenhagen, Denmark; Department of Surgery, The Angeles Clinic, Cedars Sinai Medical Center, Los Angeles, USA; Department of Dermatology and Skin Cancer, Aix Marseille University, Hôpital Timone, Marseille, France; First Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; Department of Radio-Oncology, University Hospital Zürich, University of Zürich, Zürich, Switzerland; Department of Academic Surgery, Royal Marsden NHS Foundation Trust, London, UK; Department of Dermatology, Medical University of Vienna, Vienna, Austria; AP-HP Dermatology, Université de Paris, Paris; INSERM U976, Hôpital Saint Louis, Paris, France; Early Phase Clinical Trials Unit, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy; Department of Medical Oncology, Hospital General Universitario Gregorio Marañon, Madrid, Spain; Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK; Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium; Sahlgrenska Cancer Center, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Dermatology Service, Hospital Clínic de Barcelona and University of Barcelona, Barcelona; Institut d’Investigacions Biomèdiques August i Pi Sunyer, Barcelona; CIBERER, Instituto de Salud Carlos III, Barcelona, Spain; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Department of Dermatology, University Hospital Würzburg, Würzburg, Germany; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Dermatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Charité Comprehensive Cancer Center, Charité e Universitätsmedizin Berlin, Berlin, Germany